Skip to main content
. 2021 Jan 14;11:1393. doi: 10.1038/s41598-021-81164-0

Figure 1.

Figure 1

Expression of the AR-V7 variant in LNCaP-AR-V7 and VCaP-AR-V7 cells. (a) Schematic representation of full-length AR and AR-V7 variant showing the exon structure and protein domain structure NTD, N terminal domain; DBD, DNA binding domain; H, hinge region; LBD, ligand-binding domain. (b) LNCaP-AR-V7 cells were changed to medium containing charcoal-stripped serum (CSS) and treated with vehicle (EtOH), R1881 (10 nM), or Doxycycline (Dox) (20 ng/ml for LNCaP-AR-V7) for 24 h and cells harvested for western blot analysis with AR441 and tubulin antibodies. (c, d) LNCaP-AR-V7 cells were treated as described in (b), RNA isolated and AR target gene PSA, and the AR-V7 specific target gene, EDN2 were measured using RT-qPCR. (e) VCaP-AR-V7 cells were changed to medium containing charcoal-stripped serum (CSS) and treated with vehicle (EtOH), R1881 (10 nM), or Doxycycline (Dox) (100 ng/ml for VCaP-AR-V7) for 24 h and cells harvested for western blot analysis with AR441 and tubulin antibodies (high and low exposures are shown). (f, g) VCaP-AR-V7 cells were treated as described in (e), RNA isolated and AR target gene PSA, and the AR-V7 specific target gene, EDN2 were measured using RT-qPCR. Expression values were plotted as a mean of three biological replicates from the same experiment. Error bars represent SEM. Asterisks (*) signify values that differed significantly with respect to vehicle (P < 0.05 in Student's t-test).